Pear Therapeutics

We should try that

... you know, RIP Pear, like-

Yeah

... there's so many of them.

Um, so you know, that aside, yeah, there's, there's definitely a graveyard here o- of different companies.

You know, people r- really look at it from such a macro level, but without really going into too many details, right? So I, I would look at it kind of one way.

When you're creating this level of evidence, like, if this was a drug, would it be successful, right? And meaning if these outcomes were just drug outcomes, right? So if you look at Pear and where they spent all their money on opioid use disorder, you know, ended up with a, you know, app that was indicated to increase compliance to opioid use disorder outpatient therapy, right? Didn't, in their pivotal, drive abstinence, right? Which is what you wanna see in opioid use disorder.

It's just simply if that was a drug, you know, Pfizer or whoever would've just put it on the shelf as something that doesn't work.